Medical News Today (MNT)Keeping Weight Off Might Not Require Full-Dose GLP-1 Drugs, Trials Suggest

⚠️ Small Study / Early Comparative Evidence

ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN, two placebo-controlled trials published in Nature Medicine and The Lancet, evaluated maintenance strategies after high-dose GLP-1 therapy. Participants switching to oral Foundayo regained 0.9–5 kg over one year depending on prior agent; those stepping down to 5 mg tirzepatide regained 5.6 kg versus full weight loss preservation on MTD continuation.

Clinical Considerations

• Patients previously on tirzepatide showed greater rebound when switching to oral Foundayo, likely reflecting the larger initial weight loss achieved on that agent
• Placebo-arm weight regain patterns confirm the chronic-disease model: obesity physiology does not normalize after temporary pharmacotherapy
• Trial populations were pre-selected responders who tolerated treatment — findings may not generalize to patients who discontinue due to GI adverse events or cost
• Both trials were industry-sponsored; primary endpoints were superiority over placebo, not head-to-head comparison of maintenance strategies

Practice Applications

• Consider step-down or oral transition strategies for patients who have achieved weight loss plateau and face tolerability or adherence barriers to high-dose injectable therapy
• Recognize that maintenance dosing conversations are now supported by RCT-level data, strengthening the chronic-disease framing for patients and payers
• Monitor for weight regain trajectory in patients transitioning; the 5 mg step-down preserved less than MTD continuation but substantially outperformed discontinuation
• Interpret insurance and access implications cautiously — durability beyond one year remains unestablished